Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 13, 2018

Study Completion Date

June 13, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

Ibrutinib

DRUG

Pomalidomide

DRUG

Dexamethasone

DRUG

Placebo

Trial Locations (16)

2139

Concord Repatriation General Hospital, Concord

4102

Princess Alexandra Hospital, Woolloongabba

11528

'Alexandra' General Hospital of Athens, Athens

23298

Virginia Commonwealth University, Richmond

29425

Medical University of South Carolina, Charleston

31008

Clinica Universidad de Navarra, Pamplona

37007

Hospital Universitario de Salamanca, Salamanca

44195

Cleveland Clinic, Cleveland

46017

Hospital Universitario Doctor Peset, Valencia

91010

City of Hope, Duarte

02215

Dana-Farber Cancer Institute, Boston

625 00

Fakultni nemocnice Brno, Brno

708 52

Fakultni nemocnice Ostrava, Ostrava

128 08

Vseobecna fakultni nemocnice v Praze, Prague

01307

Universitätsklinikum Carl Gustav Carus, Dresden

08025

Hospital de La Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Pharmacyclics LLC.

INDUSTRY